The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Apontis Pharma AG's share price is €11.00.
Apontis Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €6.22. Hence, Apontis Pharma AG's PS Ratio for today is 1.77.
The historical rank and industry rank for Apontis Pharma AG's PS Ratio or its related term are showing as below:
FRA:APPH'
s PS Ratio Range Over the Past 10 Years
Min: 0.48 Med: 1.82 Max: 5.57
Current: 1.77
During the past 7 years, Apontis Pharma AG's highest PS Ratio was 5.57. The lowest was 0.48. And the median was 1.82.
FRA:APPH's PS Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.315
vs FRA:APPH: 1.77
Apontis Pharma AG revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Apontis Pharma AG was 30.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.80% per year.
During the past 7 years, Apontis Pharma AG's highest 3-Year average Revenue per Share Growth Rate was 11.70% per year. The lowest was -2.00% per year. And the median was -1.10% per year.
Back to Basics: PS Ratio
Apontis Pharma AG (FRA:APPH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Apontis Pharma AG PS Ratio Related Terms
Apontis Pharma AG PS Ratio Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Apontis Pharma AG's Share Price of today is €11.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apontis Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €6.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Apontis Pharma AG (FRA:APPH) has a PS Ratio of 1.77 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Apontis Pharma AG and its competitors. This is near median its historical median of 1.82. Over the past decade, Apontis Pharma AG's PS Ratio has ranged from 0.48 to 5.57.
Is Apontis Pharma AG's PS Ratio too high?
Apontis Pharma AG's current PS Ratio of 1.77 is near median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 5.57. The Drug Manufacturers industry median PS Ratio is 2.32. Apontis Pharma AG's value of 1.77 is 23.5% below this industry median. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's PS Ratio compare to ZTS and UTHR?
Apontis Pharma AG's PS Ratio of 1.77 can be compared against companies in the Drug Manufacturers industry. The industry median PS Ratio is 2.32. Apontis Pharma AG's value of 1.77 is 23.5% below this benchmark. Historically, Apontis Pharma AG's own PS Ratio has ranged from 0.48 to 5.57 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 2.32, Apontis Pharma AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apontis Pharma AG's current PS Ratio of 1.77 is 23.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current PS Ratio is 1.77, which is near median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current PS Ratio of 1.77. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current PS Ratio is 1.77, which is near median its 10-year median of 1.82 and 23.5% below the Drug Manufacturers industry median of 2.32. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current PS Ratio is 1.77 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
PS Ratio: 1.77 (near median its 10-year median of 1.82)
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
Industry Position: 23.5% below the Drug Manufacturers median
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
